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Women and Heart Disease
In women, cardiovascular disease (CVD) is the leading cause of death 
and, despite great strides in reducing mortality from CVD, the number of 
women dying because of CVD has increased recently.1 The increase in 
mortality has been attributed, in part, to the risk of death in younger 
women with CVD due to a lack of recognition and undertreatment of 
young women with CVD.2 CVD is also the leading cause of maternal 
mortality, accounting for one in three maternal deaths.3 The peripartum 
and postpartum risk of CVD mortality is only one part of the risk to a young 
woman’s health. Pregnancy also identifies women who may be at a 
greater risk of CVD, based on the development of adverse pregnancy 
outcomes (APOs), and, in essence, may identify women who could benefit 
from atherosclerotic CVD (ASCVD) risk reduction efforts. As such, APOs 
are considered as risk enhancers of ASCVD by the 2018 American College 
of Cardiology (ACC)/American Heart Association (AHA) guideline on the 
management of blood cholesterol and the 2019 ACC/AHA guideline on the 
primary prevention of CVD.4,5 Identifying women with such risk enhancers 
and addressing ASCVD risk has been identified as an important component 
of care in the ‘fouth trimester’, which should involve comprehensive care 
and risk assessment within the 12-week postpartum period.6
The risk of APOs is not rare, with approximately 30% of women 
experiencing an APO. This includes gestational hypertension (3–14% of 
births), pre-eclampsia (2–5% of births), gestational diabetes (5%), preterm 
delivery (6–12%) and the delivery of a small-for-gestational-age (SGA) 
infant (prevalence varies by country; Table 1).7 APOs occur more frequently 
in black and Asian women, who often present with more severe clinical 
presentations and have poorer outcomes.8–10 There are numerous 
observational studies showing a strong association between these APOs 
and CVD, including premature CVD.7,11–15 Identifying women with a history 
of APOs provides a unique opportunity to identify women at risk for CVD 
and initiate early primary prevention efforts in a higher-risk group before 
the onset of adverse cardiovascular events. The American College of 
Obstetrics and Gynecology and the AHA have proposed a new paradigm 
for postpartum care to identify women at risk for future CVD, aptly named 
the ‘fourth trimester’.6,16 The purpose of this paper is to discuss the effects 
of pregnancy and APOs on the risk of CVD.
Pregnancy as a Stress Test
Pregnancy is a physiological stress test to the heart. During pregnancy, 
there is an increase in circulating blood volume. This occurs in the setting 
of a reduction in systemic vascular resistance, lower blood pressure and 
increased cardiac output, which is essential for the optimal growth of the 
developing foetus.17 These adaptive changes are designed to provide 
adequate uteroplacental circulation, given the increased metabolic 
demands during the gravid state. Insufficient haemodynamic changes can 
result in significant maternal and fetal morbidity and mortality. In addition, 
even after these acute issues resolve, some studies have shown an 
association between APOs and hypertension, left ventricular changes, 
vascular dysfunction, chronic kidney disease and CVD after the 
reproductive years.12,18–23
Adverse Pregnancy Outcomes and Associated 
Adverse Cardiovascular Outcomes
Gestational hypertension and pre-eclampsia have been associated with a 
2- to 4-fold increased risk of CHD, heart failure and stroke, with recurrent 
pre-eclampsia having the highest risk.24–26 Although the relative risk is 
highest within the first year postpartum, the risks persist decades after the 
pregnancy, when the absolute risks are greater than those immediately 
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postpartum.25,26 Hypertensive disorders of pregnancy (HDP) are associated 
with accelerated cardiovascular aging, with a greater prevalence of 
subclinical atherosclerosis and arterial stiffness index among women aged 
>40 years.26,27 In addition, HDP have been associated with aortic stenosis 
and mitral regurgitation, as demonstrated by the UK Biobank cohort, 
showing that the CVD risk goes beyond the impact of just the development 
of chronic hypertension.26 
Women who had gestational diabetes have up to seven- and twofold 
increased risks of developing type 2 diabetes and major cardiovascular 
events (independent of type 2 diabetes), respectively, than those without 
gestational diabetes.28,29 Studies have shown a 16–29% cumulative 
incidence of diabetes after 10–20 years of follow-up in women with 
gestational diabetes.30,31 Preterm delivery has been associated with a 1.4- to 
2-fold risk of CVD, CHD and stroke.12,32 The highest risks occurred when the 
deliveries occurred before 32 weeks gestation or in medically indicated 
preterm deliveries.12 
A recent study showed that at 5 years postpartum, the incidence of MI 
increased more rapidly in preterm than term deliveries, whereas for 
ischaemic stroke this occurred after 10 years.33 A recent meta-analysis did 
not pool studies on women with delivery of a SGA infant due to variations in 
the definition of SGA between the studies.34 However, the authors of that 
analysis noted a consistent trend of increased CVD risk in these women 
across all 10 studies included, with an effect estimate ranging between 1.09 
and 3.50 and a follow-up period of up to 21 years.34
Mechanisms Driving the Association 
Between Adverse Pregnancy Outcomes 
and Cardiovascular Disease
APOs are common and, although they are separate diagnoses, all these 
disorders seem to share an underlying pathogenesis, including placental 
ischaemia, maternal inflammation and vascular dysfunction.35–39 What is 
not clear is whether the APO itself initiates a pathway that results in CVD 
or whether the APO uncovers a woman’s predisposition to CVD (Figure 1). 
Regardless, APOs have immediate risks to maternal and fetal health, in 
addition to longer-term CVD consequences.7,12,40,41 As such, the occurrence 
of APOs provides an insight into a woman’s future cardiovascular health.
Systemic Endothelial/Microvascular Dysfunction 
APOs appear to share similar metabolic and/or vascular abnormalities, 
which are reflected within the placenta. In a pregnancy without any APOs, 
the maternal spiral arteries widen after a trophoblast invasion, resulting in 
low-resistance blood flow in the uteroplacental unit.37 In contrast, in a 
pregnancy affected by pre-eclampsia, the trophoblast invasion is shallow, 
with inadequate spiral artery remodelling that results in poor perfusion of 
the placenta, placental ischaemia and oxidative stress. There is also 
evidence of inflammatory markers within the maternal blood in those with 
APOs, which are not seen in those with an uncomplicated pregnancy.37,42–44 
Theoretically, the inflammatory state and the anti-angiogenic state could be 
the shared mechanisms by which APOs increase underlying CVD risk.45 
Placental lesions have also been associated with cardiovascular risk 
factors.46–48 Increased soluble fms-like tyrosine kinase-1 has been associated 
with atherosclerosis.49
Furthermore, women exposed to pre-eclampsia may also have arterial 
stiffness or endothelial damage, which, in turn, are related to their increased 
long-term CVD risk.50,51 Women with spontaneous preterm delivery have 
been observed to have a proinflammatory phenotype, with higher C-reactive 
protein levels during pregnancy.52,53 It may be that the inflammatory 
processes associated with preterm delivery increase the risk of endothelial 
dysfunction and subclinical vascular disease, and consequently increase 
CVD risk in the future.52,54 
In addition, because placental dysfunction may be due to vascular and 
endothelial cell dysfunction, women who have subclinical CVD phenotypes 
may not be able to mount an appropriate haemodynamic response in 
pregnancy. For example, placental growth factor, a hormone that promotes 
angiogenesis, is significantly reduced in pregnancies with pre-eclampsia, 
with or without SGA infants.55,56 The shared placental and maternal vascular 
characteristics in those with APOs support an overlapping pathophysiology 
for future CVD, regardless of how different the APOs appear in their 
presentation.
Cardiac and Coronary Changes
Structural changes in the myocardium can occur in women with APOs. In 
pre-eclampsia specifically, afterload-dependent cardiac remodelling can 
be seen that is similar to the remodelling of the myocardium seen in 
hypertension. Specifically, an increase in left ventricular wall thickness, 
particularly concentric left ventricular hypertrophy, has been seen even in 
those with mild gestational hypertension.57,58 Diastolic dysfunction and 
impaired left ventricular relaxation have been documented in patients 
with pre-eclampsia.58 Left atrial remodelling may also develop, most 
noted in preterm pre-eclampsia.59 These changes can also persist many 
years after the incident pregnancy.22,23 
Furthermore, women with previous pre-eclampsia had higher carotid 
intima–media thickness, lower coronary flow reserve and higher high-
sensitivity C-reactive protein values than those without pre-eclampsia.60 In 
addition, both pre-eclampsia and high parity number have been linked 
with accelerated atherosclerosis.27,61 Women with previous preterm births 
also have higher atherogenic lipids and carotid arterial wall thickening in 
the decade after delivery than women who had term births.62 For women 
with ischaemia without obstructive coronary artery disease, a history of 
APO is associated with lower coronary flow reserve suggestive of coronary 
microvascular dysfunction.63
Role of Cardiovascular Disease Risk Factors
APOs and CVD share ASCVD risk factors, and women with APOs have 
been shown to have a higher CVD risk factor burden, with a greater 
prevalence of hypertension, hyperlipidaemia, diabetes, kidney disease, 
obesity and tobacco use, in addition to a greater risk of developing these 
risk factors several years after the pregnancy.7,64–66 Except for tobacco 
use, which is inversely associated with pre-eclampsia, the other 




Gestational diabetes Any degree of glucose intolerance with its onset or 
first recognition during pregnancy 
Gestational hypertension New hypertension that develops after week 20 of 
pregnancy without proteinuria
Pre-eclampsia New hypertension that develops after week 20 of 
pregnancy, with proteinuria or evidence of 
end-organ dysfunction 
Preterm delivery Delivery before 37 weeks gestational age 
(regardless of cause)
Small-for-gestational age Birthweight in the 10th percentile or less for 
gestational age
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biochemical risk factors have been shown to persist in women years after 
HDP.67 Therefore, pre-eclampsia and gestational hypertension may be 
independent risk factors for future CVD because the post-pregnancy body 
may not fully recover from the damage to the vascular, endothelial and 
metabolic systems during pregnancy. With further insults to the body over 
time, the damage sustained during pregnancy may manifest in later life as 
cardiovascular events.68 Women with pre-existing cardiovascular risk 
factors, such as an adverse lipid profile and glucose status, are also at 
increased risk of preterm delivery.69 Similarly, delivery of SGA infants is 
linked to the development of maternal hyperlipidaemia, hypertension and 
increased calculated 10-year CVD risk prior to the onset of CVD.70,71 
Nonetheless, the excess risk based on risk factors does not fully account 
for the amount of CVD seen women with APOs.72 Therefore, other 
mechanisms are likely to be involved in the association between APOs 
and CVD.
Other Mechanisms
Families of women with an APO also have increased risks of APOs and 
CVD, suggesting that underlying genetic factors may also contribute to 
the association.73,74 Women at risk of APOs and CVD may also have genetic 
mutations that are involved in the disease process. For example, there are 
maternal sequence variants associated with both pre-eclampsia and 
hypertension.75 Similarly, genetic predisposition to hypertension has been 
associated with HDP.76 Furthermore, an association was found between 
single nucleotide polymorphism variations in genes for cholesterol 
metabolism and preterm delivery.77
Conversely, multifactorial mechanisms may explain the association of APO 
with CVD, and socioeconomic factors have also been considered. For 
example, CVD and high parity number are both more frequently observed 
in low socioeconomic classes.78 High parity number is also associated 
with a small increased future paternal CVD risk.79–81 Because the observed 
associations in both mothers and fathers attenuated following adjustment 
for lifestyle factors, there may be residual confounding by socioeconomic 
class and/or lifestyle.80
Evolving Role of Adverse Pregnancy Outcomes 
in the Prediction of Cardiovascular Disease Risk
CVD risk assessment and stratification in women remain complex and, 
historically, have underestimated risk, especially in young women.82 Not 
only do traditional CVD risk factors such as hypertension, hyperlipidaemia 
and tobacco use, among others, need to be considered, but additional 
sex-specific factors, such as APOs, should also be included. However, 
existing risk stratification schemes, such as the ASCVD Pooled Cohort 
Equations model, do not include pregnancy or other gynaecological 
history.82 Whether routine incorporation of pregnancy complications 
improves the ability to risk stratify women for CVD is unknown and has 
more recently been investigated. The HUNT study by Markovitz et al. 
assessed the long-term risk of CVD, including MI, CHD and stroke, in 
women without prior CVD history in approximately 18,000 subjects with a 
prevalence of APOs of 39%.11 In that study, of all APOs, only pre-eclampsia 
was associated with increased CVD risk. The inclusion of pregnancy 
complications only led to the reclassification of 0.4% of women without 
events into lower-risk categories and 2% of women with events were 
correctly reclassified into higher-risk categories.11 A similar study by 
Timpka et al. assessed HDP and low birth weight in subjects aged ≥50 
years and found that the inclusion of these APOs did not significantly 
improve CVD risk prediction.83 In the US, Stuart et al. studied the role of 
HDP and parity in a cohort of women aged ≥40 years without CVD risk 
factors or history of CVD.24 HDP and parity were added to the ASCVD 
Pooled Cohort Equations model, and these variables were associated 
with elevated ASCVD risk independent of established CVD risk factors; 
however, the risk reclassification across risk groups or age stratification 

























APOs = adverse pregnancy outcomes; CAC = coronary artery calcium; CVD = cardiovascular disease; IHD = ischaemic heart disease.
Figure 1: Impact of Adverse Pregnancy Outcomes on the Cardiovascular System
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were reclassified into a higher-risk group, but 8.3% of women previously 
classified as being of intermediate risk were incorrectly reclassified as 
low risk.24 Dam et al. compared CVD risk prediction in women with and 
without a history of HDP among the Framingham Risk Score, the Pooled 
Cohort Equations model and the Systematic Coronary Risk Evaluation 
(SCORE) model, and similarly found that none of the models was more 
predictive in women with than without a history of HDP.84 Although these 
studies do not demonstrate improved discrimination of risk with the 
inclusion of APOs, this may be explained by underlying embedded 
association of APO risk with traditional CVD risk factors such as 
hypertension and diabetes. 
APOs serve as a ‘window’ into future CVD risk, either through development 
of traditional CVD risk factors and/or an independent association with 
underlying vascular dysfunction. As such, it is important to screen for 
APOs as risk markers to guide potential risk mitigation strategies. In 2018, 
the ACC/AHA cholesterol guidelines for the first time acknowledged APOs 
as CVD ‘risk enhancers’ for consideration of statin use in women with 
borderline to intermediate risk, as calculated by the Pooled Cohort 
Equation.4 The inclusion of APOs among other risk enhancers allows 
clinicians to personalise decision making regarding statin therapy beyond 
just generalised risk assessment. The ACC/AHA cholesterol guidelines 
also recommend the consideration of coronary artery calcium (CAC) 
assessment to help further guide decisions regarding statin therapy.4 The 
use of CAC to guide prevention therapies, such as statins, is particularly 
intriguing in women with a history of APOs. 
Several studies have noted an association between coronary CT 
angiography (CTA)/calcium scoring in young women and a history of APOs 
(Figure 2). Benschop et al. found that, compared with women without a 
history of pre-eclampsia, pre-eclampsia is independently associated with 
CAC even when accounting for traditional CVD risk factors.85 Another 
study assessed a broader set of APOs in Black women, including preterm 
delivery, pre-eclampsia and gestational diabetes, against matched 
controls without APOs with regard to coronary CTA findings.86 In that 
study, any APO was associated with higher rates of atherosclerotic 
coronary disease, defined as ≥20% luminal narrowing disease and 
obstructive ≥50% luminal narrowing disease. That study was particular 
important because research in this area in Black women, who have high 
rates of pregnancy complications, is lacking. Whether coronary CTA 
should play a more routine role in assessing CVD risk in women with APOs 
is unknown and an area in need of further study.
Conclusion
Associations of APOs with future CVD have been reported in the literature. 
However, the underlying causal mechanisms remain unknown. It is 
important to raise awareness of the importance of these associations and 
the current recommendations among healthcare professionals, as well as 
among the women themselves. Further research is needed to elucidate 
the pathophysiology behind these associations. This, in turn, will inform 
future research in the role of ASCVD risk assessment and the effect of 
aggressive ASCVD risk modification on CVD outcomes in women with a 
history of APOs. 
Traditional CVD risk factors
History/examination/risk assessmentHyperlipidaemia
Assess for APOs
Assess for other ASCVD risk
enhancers
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